“ations. As a development stage company, we expect to incur significant and increasing losses until regulatory approval is granted for palazestrant or OP-3136. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term. We have never generated revenue from product sales and may never be profi…”
Runway
fact
Cash of $461M against operating outflow of $55M per quarter gives roughly 8.4 quarters of runway, clearing the registered primary completion 0.7 quarters out by 7.7 quarters.
87,497,607 shares outstanding against 106,431,993 if every outstanding option, warrant and convertible were exercised. In that case 17.8% of a gain in enterprise value would accrue to those holders rather than to current shareholders.
6 approved products already carry Breast Cancer on label, including Doxorubicin Hydrochloride, capecitabine, Docetaxel, Fulvestrant. Approval would enter an occupied market.
Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug, PRIME (EU). These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.
This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.